Is TSPT a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

317 people get TSPT articles and Market Currents by email alert.

Get email alerts on TSPT »

HEADLINES:

SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Transcept: Throwing In The Towel On Intermezzo
Smith On Stocks • Thu, May 9 • 3 Comments
Transcept Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Transcept Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire (May 8, 2013)
Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013

PR Newswire (May 1, 2013)
Thomas J. Dietz, Ph.D., Appointed To The Transcept Pharmaceuticals Board Of Directors

PR Newswire (Apr 10, 2013)
Transcept Pharmaceuticals to Present at Cowen and Company Health Care Conference on March 6

PR Newswire (Feb 28, 2013)
Transcept Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 27
Transcept Pharmaceuticals Reports Fourth Quarter And Full Year 2012 Financial Results

PR Newswire (Feb 27, 2013)
Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Financial Results and Host Conference Call on February 27, 2013

PR Newswire (Feb 21, 2013)
Transcept: The Prescription Trend Watch For Intermezzo Is On
Smith On Stocks • Thu, Feb 14 • 9 Comments
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences

PR Newswire (Feb 5, 2013)
Transcept: Purdue Fires Big Marketing Guns And FDA Issues Insomnia Drug Guidelines That Help Intermezzo
Smith On Stocks • Wed, Jan 23
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements for Zolpidem Based Prescription Sleep Aids Administered at Bedtime

PR Newswire (Jan 10, 2013)
Transcept Pharmaceuticals Announces that a Phase 2 Clinical Trial of TO-2061 as Adjunctive Therapy for Obsessive Compulsive Disorder Did Not Meet Primary Endpoint

PR Newswire (Dec 21, 2012)
Transcept: Direct To Consumer Advertising Campaign Could Be Tipping Point For Intermezzo
Smith On Stocks • Fri, Dec 7, 2012 • 13 Comments
What Is Next For Transcept Pharmaceuticals After Disappointing Intermezzo Launch?
LifeSci Advisors • Thu, Dec 6, 2012 • 2 Comments
Transcept Pharmaceuticals to Host Conference Call to Discuss Broadened Intermezzo® Commercialization Strategy and New Consumer Advertising Campaign by Purdue Pharma

PR Newswire (Nov 26, 2012)

To learn more about Seeking Alpha Pro, click here.

Transcept: Throwing In The Towel On Intermezzo
Smith On Stocks • Thu, May 9 • 3 Comments
Transcept: The Prescription Trend Watch For Intermezzo Is On
Smith On Stocks • Thu, Feb 14 • 9 Comments
Transcept: Purdue Fires Big Marketing Guns And FDA Issues Insomnia Drug Guidelines That Help Intermezzo
Smith On Stocks • Wed, Jan 23
Transcept: Direct To Consumer Advertising Campaign Could Be Tipping Point For Intermezzo
Smith On Stocks • Fri, Dec 7, 2012 • 13 Comments
What Is Next For Transcept Pharmaceuticals After Disappointing Intermezzo Launch?
LifeSci Advisors • Thu, Dec 6, 2012 • 2 Comments
Transcept: The Intermezzo Launch Is Underway
Smith On Stocks • Tue, Apr 24, 2012 • 2 Comments
Transcept's Intermezzo Has Significant Long-Term Potential, But What About 2012?
Smith On Stocks • Tue, Jan 24, 2012 • 11 Comments
Transcept's Intermezzo: A Blockbuster In The Making
ScriptVolume • Tue, Jan 3, 2012 • 16 Comments
Transcept Wins FDA OK For Insomnia Drug, What's Next?
Kinetic Investments • Wed, Nov 23, 2011 • 18 Comments
Focus On Transcept As Intermezzo's Fate Awaits FDA
Todd Johnson • Tue, Nov 22, 2011 • 14 Comments
Transcept Resubmits Their Intermezzo Application To The FDA
M. E. Garza • Thu, Sep 29, 2011 • 1 Comment
Transcept Up Sharply On Plan To Resubmit Intermezzo NDA
Smith On Stocks • Thu, Sep 15, 2011 • 1 Comment
Transcept Gets Some Disappointing News
Smith On Stocks • Wed, Jul 13, 2011 • 8 Comments
More Details on Transcept's Intermezzo Efforts and Pending FDA Action
Smith On Stocks • Tue, Jul 12, 2011 • 11 Comments
Transcept: Management Confident as FDA Decision Nears
Alex Shadunsky • Mon, Jul 11, 2011 • 1 Comment
What Happens After Intermezzo's Likely FDA Approval
Smith On Stocks • Mon, Jul 11, 2011 • 5 Comments
Is Transcept Pharma's Tumble Justified?
Spencer Knight • Mon, Jul 11, 2011 • 6 Comments
Transcept: Interest Rising Ahead of PDUFA Date Next Week
Alex Shadunsky • Thu, Jul 7, 2011 • 1 Comment
Why Transcept Pharmaceuticals Is Still Undervalued
Jason Napodano • Sun, Jan 16, 2011 • 15 Comments
FDA Reaction to Transcept Insomnia Drug Trial Data Can Go Either Way
Proactive Investor • Wed, Oct 20, 2010 • 3 Comments

SmithOnStocks Opines On Stocks: May 19th Edition
Smith On Stocks • Sun, May 19 • 12 Comments
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Meetings With Management: JPM Healthcare And The Biotech Showcase
PropThink • Fri, Jan 11 • 19 Comments
6 Stocks To Watch Post Earnings On Tuesday Morning
Chandrasekhar Rajagopalan • Tue, Nov 13, 2012
Noteworthy Institutional 5% Ownership Filings On Friday
GuruFundPicks • Mon, Apr 2, 2012 • 1 Comment
3 Stocks With High Short Interest: 2 Buys, 1 Sell
Scott Matusow • Fri, Feb 10, 2012 • 3 Comments
The Best Biotech Stocks Of 2012
Michael J. Ray • Mon, Jan 23, 2012 • 30 Comments
BioMimetic Therapeutics: The FDA Gives A Smudged Map For The Minefields
Stephen Simpson • Thu, Jan 5, 2012 • 1 Comment
Twelve Biotech Picks For 2012
Jason Napodano • Thu, Dec 22, 2011 • 9 Comments
20 Biotech Stocks That Hedge Funds Are Selling
Kapitall • Sun, Dec 11, 2011 • 1 Comment
Investors And Traders In The Biotech Landscape
Michael J. Ray • Tue, Dec 6, 2011 • 11 Comments
Speculative Biotech: A Speculation Trader's Dream and Nightmare
Spencer Knight • Thu, Nov 3, 2011 • 3 Comments
5 Pharma Companies With November Catalysts
Spencer Knight • Tue, Nov 1, 2011 • 2 Comments
1 Biotech To Buy And 6 FDA Decision-Pending Biotechs To Avoid
Todd Johnson • Thu, Oct 27, 2011 • 58 Comments
End Of Year Fireworks For The Biotech Sector
Michael J. Ray • Mon, Oct 24, 2011 • 24 Comments
Upcoming FDA Approval Decision Dates for Q4 2011 - How You Can Profit
David Zanoni • Thu, Oct 6, 2011 • 9 Comments
Top Picks From Tuesday's Big News Movers
GuruFundPicks • Wed, Oct 5, 2011 • 1 Comment
Small Cap Biotech: Top Buy And Sell Ideas Based On Last Week's Big News, Price Movers
GuruFundPicks • Mon, Sep 19, 2011 • 2 Comments
5 Stocks In The News That Swung In Thursday Trading
Brian Nichols • Fri, Sep 16, 2011
A Look at 2 Undervalued Biotech Stocks
Alex Shadunsky • Mon, Aug 15, 2011 • 3 Comments

Transcept Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Transcept Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 27
Transcept's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Mon, Nov 12, 2012
Transcept Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Aug 13, 2012

Transcept Pharmaceuticals Reports First Quarter 2013 Financial Results

PR Newswire (May 8, 2013)
Transcept Pharmaceuticals to Report First Quarter 2013 Financial Results and Host Conference Call on May 8, 2013

PR Newswire (May 1, 2013)
Thomas J. Dietz, Ph.D., Appointed To The Transcept Pharmaceuticals Board Of Directors

PR Newswire (Apr 10, 2013)
Transcept Pharmaceuticals to Present at Cowen and Company Health Care Conference on March 6

PR Newswire (Feb 28, 2013)
Transcept Pharmaceuticals Reports Fourth Quarter And Full Year 2012 Financial Results

PR Newswire (Feb 27, 2013)
Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Financial Results and Host Conference Call on February 27, 2013

PR Newswire (Feb 21, 2013)
Transcept Pharmaceuticals to Present at Two Upcoming Investor Conferences

PR Newswire (Feb 5, 2013)
Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements for Zolpidem Based Prescription Sleep Aids Administered at Bedtime

PR Newswire (Jan 10, 2013)
Transcept Pharmaceuticals Announces that a Phase 2 Clinical Trial of TO-2061 as Adjunctive Therapy for Obsessive Compulsive Disorder Did Not Meet Primary Endpoint

PR Newswire (Dec 21, 2012)
Transcept Pharmaceuticals to Host Conference Call to Discuss Broadened Intermezzo® Commercialization Strategy and New Consumer Advertising Campaign by Purdue Pharma

PR Newswire (Nov 26, 2012)
Transcept Pharmaceuticals Announces Broadened Intermezzo® Commercialization Strategy Including Initiation of a Direct to Consumer Advertising Campaign by Purdue Pharma

PR Newswire (Nov 26, 2012)
Transcept Pharmaceuticals Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 12, 2012)
Transcept Pharmaceuticals to Report Third Quarter 2012 Financial Results and Host Conference Call on November 12, 2012

PR Newswire (Nov 6, 2012)
Transcept Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Trial of TO-2061 Added as Adjunctive Therapy for Obsessive Compulsive Disorder

PR Newswire (Sep 12, 2012)
Transcept Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

PR Newswire (Sep 4, 2012)
Transcept Pharmaceuticals Announces Listing of New U.S. Patent for Intermezzo in FDA's Orange Book

PR Newswire (Aug 21, 2012)
Transcept Pharmaceuticals Reports Second Quarter 2012 Financial Results

PR Newswire (Aug 13, 2012)
Transcept Pharmaceuticals to Report Second Quarter 2012 Financial Results and Host Conference Call on August 13, 2012

PR Newswire (Jul 30, 2012)
Transcept Pharmaceuticals to Present at the JMP Securities Healthcare Conference

PR Newswire (Jul 5, 2012)
Transcept Pharmaceuticals Appoints Leone Patterson as Vice President and Chief Financial Officer

PR Newswire (Jun 26, 2012)

TSPT vs. ETF Alternatives

Company Description

Transcept Pharmaceuticals, Inc., or Transcept, was incorporated in Delaware in 2001 as Novacea, Inc., or Novacea. Prior to January 2008, Novacea had been principally engaged as a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, April 26, 5:11 PM Transcept Pharmaceuticals (TSPT) files a mixed-shelf to sell in the aggregate up to $75M in securities from time to time in one or more offerings. Comment! [Healthcare]
Wednesday, February 27, 6:09 PM Transcept Pharmaceuticals (TSPT): Q4 EPS of -$0.35 misses by $0.07. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 25, 4:39 PM Transcept Pharmaceuticals (TSPT) says that on February 21 it received a new Paragraph IV notice letter from Dr. Reddy's Laboratories (RDY) advising that it's filed an Abbreviated New Drug Application with the FDA for generic versions of Intermezzo. Comment! [Healthcare]
Friday, January 11, 11:53 AM Transcept Pharmaceuticals (TSPT +6.8%) gets some follow-through off yesterday's +10% run, moving higher again today off the news that its sleep drug Intermezzo dodged an FDA bullet requiring a number of other sleep aids to reduce their dosage due to the risk of impaired cognitive function issues. The drug is the company's first FDA approved product. Comment! [Healthcare, On the Move]
Thursday, January 10, 4:01 PM Transcept Pharmaceuticals (TSPT +9.8%) gets a big boost from U.S. regulators today after the FDA declined to lower the recommended dose of it's Intermezzo prescription sleep aid because the drug's label already recommends a lower dosage for women than men because of their smaller average size. The agency said it believes the bedtime dose of Ambien, Edluar and Zolpimist should be reduced from 10 milligrams to 5 milligrams because the drugs can impair alertness and driving ability in some people the next morning. Comment! [Healthcare, On the Move]
Friday, December 21, 2012, 7:39 AM Transcept Pharmaceuticals (TSPT) announces poor results in Phase 2 testing of its TO-2061 pills in patients with OCD. Shares remain halted. Update at 9:10 ET: Shares are off 14.7% premarket. (PR) Comment! [Healthcare, Breaking News, On the Move]
Friday, December 21, 2012, 7:29 AM Transcept Pharmaceuticals (TSPT) is halted with news pending. Comment! [Healthcare, Breaking News]
Tuesday, November 27, 2012, 12:45 PM Midday top 10 gainers: ACAD +141%. CPSL +30%. IMMR +30%. RAH +27%. TSPT +12%. BWEN +12%. CUR +12%. FOLD +10%. FONR +10%. CDTI +10%. Midday top 10 Losers: STV -11%. MMR -9%. THO -11%. RECV -10%. CBAK -9%. BLIN -12%. ENMD -8%. RGDX -8%. ARCI -8%. BV -8%. Comment!
Monday, November 26, 2012, 6:28 PM Transcept Pharmaceuticals (TSPT) says that its marketing partner for Intermezzo, Purdue Pharmaceutical Products, is launching a national direct-to-consumer promotional campaign, which will include digital, print and television advertising. Purdue has already committed $19M to the project, and TSPT plans to provide an additional $10M. The program will be rolled out over the first six months of 2013. TSPT will host a conference call to discuss its marketing strategy on Tuesday, November 27 at 8:30 a.m. EST. Comment! [Healthcare]
Monday, November 12, 2012, 5:45 PM After-hours top gainers, as of 5:15 p.m.: SNTA +19.8%. IQNT +18.7%. LPH +10.2%. TSPT +8.9%. CSOD +8.1%.
After-hours top losers: INFI -8.6%. SCLN -5.5%. EVER -4.4%. GME -4.1%. MWE -3.7%. Comment! [On the Move]
Monday, November 12, 2012, 4:46 PM More on Transcept Pharmaceuticals (TSPT): Q3 easily beats estimates across the board. Revenue topped consensus expectations, boosted in part by a $10M milestone payment from Purdue Pharmaceutical for the listing of a TSPT method of use patent in the FDA's Orange Book, while better EPS performance was driven by lower R&D expenses. Shares +3.5% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, November 12, 2012, 4:29 PM Transcept Pharmaceuticals (TSPT): Q3 EPS of $0.25 beats by $0.20. Revenue of $10.4M beats by $2M. Shares +3.5% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Wednesday, August 22, 2012, 2:07 PM Trancept Pharmaceutical (TSPT +5.8%) bounces on the FDA's listing of the drug maker's insomnia treatment Intermezzo in its "Orange Book." The patent has an expiry of 2029, which gives the company a considerable amount of time to fend off generic competition. The market for sleep aids is enormous, with 79M prescriptions filled annually in the U.S., and each 1% share of that market equates to roughly $150M in Intermezzo sales. Comment! [Healthcare, On the Move]
Monday, June 4, 2012, 5:00 PM Transcept Pharmaceuticals (TSPT) announces that John Kollins will join the Company as SVP and Chief Business Officer. In this new position, Mr. Kollins will have primary responsibility for business and corporate development activities and report directly to President and CEO Glenn Oclassen. Comment! [Healthcare]
Thursday, April 26, 2012, 9:20 AM Premarket gainers: PATK +26%. HTWR +15%. REGN +14%. NUAN +14%. LOGI +14%. VHC +12%. CTXS +12%. NRGY +10%. EQIX +9%. CRUS +8%. SPPI +8%. INCY +7%. XLNX +7%. WPI +7%. AMRN +5%. EA +7%. MWW +5%. AH +6%. PHM +6%. AIS +5%. AIXG +5%. LSI +4%. TS +3%. UN +3%. ZNGA +3%. FRO +3%. RDS +3%.
Losers: FURX -28%. PCS -15%. HRB -15%. TQNT -14%. ALU -13%. TSPT -12%. AET -9%. PTX -7%. AKAM -6%. AZN -6%. ZMH -5%. DB -5%. HERO -5%. STD -5%. DOW -4%. CELG -4%. CS -4%. CROX -4%. GG -3%. BWA -3%. UNH -3%. LVS -3%. VALE -3%. UPS -3%. POT -3%. Comment! [On the Move]
Wednesday, December 21, 2011, 5:07 PM Transcept Pharmaceuticals (TSPT) receives a $10M milestone payment from Purdue Pharma following the FDA's inclusion of Intermezzo formulation patents in its Orange Book last week. The payment is part of an agreement between the two parties for the U.S. commercialization of the drug to be launched in Q2 of 2012. Shares +0.7% AH. Comment! [Healthcare]

jsIRA
TSPT - bought 5.18. Cash 4.97/share no debt one drug on the market one in Phase II a.
10/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

freefdawatchlist
http://stks.co/3Wb3 Premarket losers $FURX $TQNT $TSPT $HERO $AKAM $CROX $CELG $MPEL Gainers $PATK $HTWR $LOGI $REGN $CTXS $SPPI $EQIX $CRUS
4/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Maria Auziliadora: Good job
4/26/12
• !Report Abuse
Maria Auziliadora: That stock will come back though that's m feeling maybe not today!!!
4/26/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Trimmed more profits in $TSPT and keeping the rest of the inventory very light. $TBT down big creates concerns of a larger correction $$
4/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
$TSPT up $1 since this morning's add....trimming profits now. $CLDX next on list to trim profits $$ #KSMT
4/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Added to $CLDX & $TSPT positions. Will trim before close, but expecting a market bounce soon unless $TBT starts falling hard under 20 $$
4/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
$TSPT trade moving right past resistance but overall volume is poor so not adding yet $$ $SPY #KSMT
3/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Kudrna
Initiated starter position in $TSPT after trimming profit in $BYD & $CLDX. Will look to increase on breakout or light vol pullback $$ #KSMT
3/28/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Kudrna: starter initiated at 10.20
3/28/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
$TSPT favorable setup for a breakout, support near 9.61 area and key resistance is 10.41. No position yet but stalking $$ $SPY #KSMT
3/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kinetic Investments
$TSPT Trancept: Time to add to shorts?
12/1/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kinetic Investments
$TSPT http://yhoo.it/tNHZZU - Transcept Pharmaceuticals Announces Purdue's Exercise of Option to Commercialize Intermezzo® in the US BW
11/30/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

freefdawatchlist
http://stks.co/3Wb3 Premarket losers $FURX $TQNT $TSPT $HERO $AKAM $CROX $CELG $MPEL Gainers $PATK $HTWR $LOGI $REGN $CTXS $SPPI $EQIX $CRUS
4/26/12
Reply (5)

• !Report Abuse
View all 5 replies
Maria Auziliadora: Good job
4/26/12
• !Report Abuse
Maria Auziliadora: That stock will come back though that's m feeling maybe not today!!!
4/26/12
• !Report Abuse
Add a reply...

140 characters

Michael Kudrna
Initiated starter position in $TSPT after trimming profit in $BYD & $CLDX. Will look to increase on breakout or light vol pullback $$ #KSMT
3/28/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Kudrna: starter initiated at 10.20
3/28/12
• !Report Abuse
Add a reply...

140 characters

Kinetic Investments
TSPT - FDA Approves Intermezzo. Trading Halted.
11/23/11
Reply (1)

• !Report Abuse
View all 1 replies
Kinetic Investments: http://1.usa.gov/tZdZjG
11/23/11
• !Report Abuse
Add a reply...

140 characters

TSPT Transcept Pharmaceuticals, Inc.

TSPT

Transcept Pharmaceuticals, Inc.